CN115197115A - Preparation method and application of chiral 5-oxopyrrolidine-3-formic acid - Google Patents
Preparation method and application of chiral 5-oxopyrrolidine-3-formic acid Download PDFInfo
- Publication number
- CN115197115A CN115197115A CN202211025942.6A CN202211025942A CN115197115A CN 115197115 A CN115197115 A CN 115197115A CN 202211025942 A CN202211025942 A CN 202211025942A CN 115197115 A CN115197115 A CN 115197115A
- Authority
- CN
- China
- Prior art keywords
- chiral
- oxopyrrolidine
- carboxylic acid
- preparation
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- GZVHQYZRBCSHAI-UHFFFAOYSA-N 5-oxopyrrolidine-3-carboxylic acid Chemical compound OC(=O)C1CNC(=O)C1 GZVHQYZRBCSHAI-UHFFFAOYSA-N 0.000 title claims abstract description 19
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000006243 chemical reaction Methods 0.000 claims abstract description 32
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 239000002994 raw material Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 8
- 238000010898 silica gel chromatography Methods 0.000 claims abstract description 7
- ZWWQRMFIZFPUAA-UHFFFAOYSA-N dimethyl 2-methylidenebutanedioate Chemical compound COC(=O)CC(=C)C(=O)OC ZWWQRMFIZFPUAA-UHFFFAOYSA-N 0.000 claims abstract description 5
- 238000010931 ester hydrolysis Methods 0.000 claims abstract description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- -1 rare earth compound cerium nitrate Amine Chemical class 0.000 claims description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 14
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 125000006239 protecting group Chemical group 0.000 claims description 11
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 8
- GZVHQYZRBCSHAI-GSVOUGTGSA-N (3r)-5-oxopyrrolidine-3-carboxylic acid Chemical compound OC(=O)[C@H]1CNC(=O)C1 GZVHQYZRBCSHAI-GSVOUGTGSA-N 0.000 claims description 7
- GZVHQYZRBCSHAI-VKHMYHEASA-N (3s)-5-oxopyrrolidine-3-carboxylic acid Chemical compound OC(=O)[C@@H]1CNC(=O)C1 GZVHQYZRBCSHAI-VKHMYHEASA-N 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 229910002651 NO3 Inorganic materials 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- GYXGAEAOIFNGAE-UHFFFAOYSA-N 2-propan-2-ylidenebutanedioic acid Chemical compound CC(C)=C(C(O)=O)CC(O)=O GYXGAEAOIFNGAE-UHFFFAOYSA-N 0.000 claims description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 5
- 238000004440 column chromatography Methods 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000035484 reaction time Effects 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- HSJPMRKMPBAUAU-UHFFFAOYSA-N cerium nitrate Inorganic materials [Ce+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O HSJPMRKMPBAUAU-UHFFFAOYSA-N 0.000 claims description 3
- 239000000741 silica gel Substances 0.000 claims description 3
- 229910002027 silica gel Inorganic materials 0.000 claims description 3
- 238000006460 hydrolysis reaction Methods 0.000 claims description 2
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims description 2
- 238000004508 fractional distillation Methods 0.000 claims 1
- 230000007062 hydrolysis Effects 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- AIJFPNKGGAPZFJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)-n-methylmethanamine Chemical compound CNCC1=CC=C(OC)C=C1 AIJFPNKGGAPZFJ-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 25
- 239000000126 substance Substances 0.000 description 14
- 239000007787 solid Substances 0.000 description 10
- 230000003287 optical effect Effects 0.000 description 9
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- JBOIQIRJYOXYDQ-KOLCDFICSA-N (3s)-1-[(1r)-1-(4-methoxyphenyl)ethyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound C1=CC(OC)=CC=C1[C@@H](C)N1C(=O)C[C@H](C(O)=O)C1 JBOIQIRJYOXYDQ-KOLCDFICSA-N 0.000 description 3
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- 150000004702 methyl esters Chemical class 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 238000012805 post-processing Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- NTPLXRHDUXRPNE-UHFFFAOYSA-N 4-methoxyacetophenone Chemical compound COC1=CC=C(C(C)=O)C=C1 NTPLXRHDUXRPNE-UHFFFAOYSA-N 0.000 description 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960002448 dasatinib Drugs 0.000 description 2
- 230000008034 disappearance Effects 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JBOIQIRJYOXYDQ-MWLCHTKSSA-N (3R)-1-[(1R)-1-(4-methoxyphenyl)ethyl]-5-oxopyrrolidine-3-carboxylic acid Chemical compound COc1ccc(cc1)[C@@H](C)N1C[C@@H](CC1=O)C(O)=O JBOIQIRJYOXYDQ-MWLCHTKSSA-N 0.000 description 1
- VYKQDWPBYULGPF-UHFFFAOYSA-N 1-benzyl-5-oxopyrrolidine-3-carboxylic acid Chemical compound O=C1CC(C(=O)O)CN1CC1=CC=CC=C1 VYKQDWPBYULGPF-UHFFFAOYSA-N 0.000 description 1
- BJSCOTHGFJMOOE-UHFFFAOYSA-N 5-oxopyrrolidine-3-carboxamide Chemical class NC(=O)C1CNC(=O)C1 BJSCOTHGFJMOOE-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- FJRTVLWHONLTLA-UHFFFAOYSA-N methyl 5-oxopyrrolidine-3-carboxylate Chemical compound COC(=O)C1CNC(=O)C1 FJRTVLWHONLTLA-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- LCAFGJGYCUMTGS-UHFFFAOYSA-N nebracetam Chemical compound O=C1CC(CN)CN1CC1=CC=CC=C1 LCAFGJGYCUMTGS-UHFFFAOYSA-N 0.000 description 1
- 229950010963 nebracetam Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- 230000001777 nootropic effect Effects 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- VIXWGKYSYIBATJ-UHFFFAOYSA-N pyrrol-2-one Chemical compound O=C1C=CC=N1 VIXWGKYSYIBATJ-UHFFFAOYSA-N 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical group O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 150000004040 pyrrolidinones Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pyrrole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Description
技术领域technical field
本发明属于药物化学与有机手性化合物制备技术领域,特别涉及一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用。The invention belongs to the technical field of medicinal chemistry and organic chiral compound preparation, in particular to a preparation method and application of a chiral 5-oxopyrrolidine-3-carboxylic acid.
背景技术Background technique
5-氧代吡咯烷-3-甲酸(化学结构如下: A),是一类重要的药物中间体,例如N-烷基或苄基取代的5-氧代吡咯烷-3-甲酸就是合成制备奈拉西坦的必须中间体原料;奈拉西坦是吡咯烷酮类结构的新型药物(Nebracetam),具有改善脑能量代谢和神经传递功能,对脑内胆碱能系统机能障碍有明显改善作用;而手性R/S构型的5-氧代吡咯烷-3-甲酸可以制备得到新型的吡咯烷酮类衍生物。5-oxopyrrolidine-3-carboxylic acid (chemical structure is as follows: A), is an important class of pharmaceutical intermediates, such as N-alkyl or benzyl substituted 5-oxopyrrolidine-3-carboxylic acid is synthesized and prepared Neiraracetam is an essential intermediate raw material; Neiraracetam is a new drug with pyrrolidone structure (Nebracetam), which can improve brain energy metabolism and neurotransmission function, and significantly improve the dysfunction of cholinergic system in the brain; and The chiral R/S configuration of 5-oxopyrrolidine-3-carboxylic acid can be used to prepare novel pyrrolidone derivatives.
5-氧代吡咯烷-3-甲酸化学名称也可以命名为2-吡咯啉酮-4-羧酸,在专利CN104447733A中研究者把1-苄基-2-吡咯啉酮-4-羧酸(1-苄基-5-氧代吡咯烷-3-甲酸)与蛋白激酶抑制剂抗肿瘤药物达沙替尼(Dasatinib)的主要药效基团片段5-芳香胺酰基-2-氨基噻唑进行化学偶联,得到了1-苄基-2-吡咯啉酮-4-酰胺类化合物,化学结构如下:The chemical name of 5-oxopyrrolidine-3-carboxylic acid can also be named as 2-pyrrolidone-4-carboxylic acid. In patent CN104447733A, researchers put 1-benzyl-2-pyrrolidinone-4-carboxylic acid ( 1-benzyl-5-oxopyrrolidine-3-carboxylic acid) with 5-arylaminoacyl-2-aminothiazole, the main pharmacophore fragment of the protein kinase inhibitor antineoplastic drug Dasatinib Coupling gave 1-benzyl-2-pyrrolidinone-4-amide compounds with the following chemical structures:
该类带有达沙替尼药效团的2-吡咯啉酮-4-酰胺类化合物能有效调节酪氨酸激酶的信号传导,抑制不良细胞增生和血管生长,具有较明显的抗肿瘤活性。The 2-pyrrolidone-4-amide compounds with dasatinib pharmacophore can effectively regulate the signal transduction of tyrosine kinase, inhibit the proliferation of undesirable cells and the growth of blood vessels, and have obvious anti-tumor activity.
综上所述,5-氧代吡咯烷-3-甲酸(2-吡咯啉酮-4-羧酸)是合成包括益智类药物和抗肿瘤化合物的关键中间体,可以预见手性的R或S构型的5-氧代吡咯烷-3-甲酸在药物化学领域会具有重要的实用价值与广泛的应用前景,故有必要提供一种手性的R或S构型的5-氧代吡咯烷-3-甲酸的制备方法与应用。In conclusion, 5-oxopyrrolidine-3-carboxylic acid (2-pyrrolidone-4-carboxylic acid) is a key intermediate in the synthesis of nootropics and antitumor compounds, and chiral R or S-configuration 5-oxopyrrolidine-3-carboxylic acid will have important practical value and broad application prospects in the field of medicinal chemistry, so it is necessary to provide a chiral R or S configuration 5-oxopyrrole Preparation method and application of alkane-3-carboxylic acid.
发明内容SUMMARY OF THE INVENTION
为了解决上述技术问题,本发明提供了一种手性5-氧代吡咯烷-3-甲酸的制备方法与应用,引入了手性中心,各手性中间体产物易于分离纯化,且具有较高的光学纯度。In order to solve the above technical problems, the present invention provides a preparation method and application of chiral 5-oxopyrrolidine-3-carboxylic acid, which introduces a chiral center, and each chiral intermediate product is easy to separate and purify, and has high optical purity.
为了达到解决上述技术问题的技术效果,本发明是通过以下技术方实现的:一种手性5-氧代吡咯烷-3-甲酸的制备方法,其特征在于,具体包括以下步骤:In order to achieve the technical effect of solving the above-mentioned technical problems, the present invention is realized by the following technical methods: a preparation method of chiral 5-oxopyrrolidine-3-carboxylic acid, which is characterized in that, specifically comprises the following steps:
S1、用起始原料衣康酸二甲酯(CAS:617-52-7)和R(+)-对甲氧基甲基苯甲胺(CAS:22038-86-4)在180℃加热反应。S1. Heating reaction with starting material dimethyl itaconic acid (CAS: 617-52-7) and R(+)-p-methoxymethylbenzylamine (CAS: 22038-86-4) at 180 °C .
作为优选,由于两个原料都是液体故没有使用其它有机溶剂,同时用分水器分出反应所生成的甲醇(CH3OH)以便促使反应进行得更完全;反应底物衣康酸二甲酯和R(+)-对甲氧基甲基苯甲胺的当量摩尔比为1:1;反应产物是一对非对映异构体的混合物。As a preference, since the two raw materials are liquid, no other organic solvent is used, and at the same time, the methanol (CH 3 OH) generated by the reaction is separated with a water separator to promote the reaction to proceed more completely; the reaction substrate is dimethyl itaconic acid. The equivalent molar ratio of ester and R(+)-p-methoxymethylbenzylamine was 1:1; the reaction product was a mixture of a pair of diastereomers.
S2、分离第一步反应生成的一对非对映异构体,其方法是采用普通的硅胶柱层析分离法。S2. Separate a pair of diastereomers generated by the first step reaction by using a common silica gel column chromatography separation method.
分离出的两个手性化合物的化学名称分别是(1R, 3R)-1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸甲酯(上面反应式中产物的前者)和(1R, 3S)-1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸甲酯(上面反应式中产物的后者),其各自的化学收率超过60%,经高压液相色谱(HPLC)分析其d.e.值都大于90%。The chemical names of the two isolated chiral compounds are (1R, 3R)-1-(1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylic acid methyl ester (the former product in the above reaction formula) and (1R, 3S)-1-(1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylic acid methyl ester (reaction above The latter products in the formula), their respective chemical yields exceed 60%, and their d.e. values are all greater than 90% by high pressure liquid chromatography (HPLC) analysis.
作为优选,柱层析所用的淋洗剂优先采用石油醚(60-90℃)和乙酸乙酯,比例(体积比)依次为3:1、2:1、1:1、1:2;石油醚(60-90℃)也可使用30-60℃的溜程范围,或者用正己烷代替;柱层析所用的硅胶可以是100-200目或者200-300目,优选200-300目。Preferably, the eluent used in column chromatography is preferably petroleum ether (60-90°C) and ethyl acetate, and the ratio (volume ratio) is 3:1, 2:1, 1:1, 1:2 in turn; Ether (60-90 ℃) can also use the running range of 30-60 ℃, or use n-hexane instead; the silica gel used in column chromatography can be 100-200 mesh or 200-300 mesh, preferably 200-300 mesh.
S3、分别以上一步分离出的两个非对映异构体继续反应经过酯水解和脱去氮上保护基,或者先脱去氮上保护基再水解酯即可得到两个构型的目标手性化合物(R)-A和 (S)-A。S3. The two diastereomers separated in the above step continue to react through ester hydrolysis and removal of the protective group on the nitrogen, or first remove the protective group on the nitrogen and then hydrolyze the ester to obtain the target molecules of the two configurations. Compounds (R)-A and (S)-A.
作为优选,所述的S2中过柱分离得到的两个非对映异构体是油状物,与氢氧化锂(LiOH)的摩尔比1:1~1:1.5,反应使用混合溶剂甲醇和水(体积比1:1),反应温度是室温20-25℃,反应时间一般为2-3小时,水解反应的化学产率都超过85%;两个产物的名称分别为(1R, 3R)-1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸和(1R, 3S)-1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸;由于这两个羧酸中间体都是固体经过重结晶可以增加其光学纯度。Preferably, the two diastereomers obtained by column separation in S2 are oily substances, and the molar ratio to lithium hydroxide (LiOH) is 1:1~1:1.5, and the reaction uses mixed solvent methanol and water. (volume ratio 1:1), the reaction temperature is room temperature 20-25°C, the reaction time is generally 2-3 hours, and the chemical yield of the hydrolysis reaction exceeds 85%; the names of the two products are (1R, 3R)- 1-(1-(4-Methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylic acid and (1R, 3S)-1-(1-(4-methoxyphenyl) Ethyl)-5-oxopyrrolidine-3-carboxylic acid; since these two carboxylic acid intermediates are solid, their optical purity can be increased by recrystallization.
作为优选,所述的羧酸产物也是互为非对映异构体,再次分别与稀土化合物硝酸铈胺(Ce(NH4)2(NO3)6)反应,脱去N上的保护基(生成对甲氧基乙酰苯)得到(3R)5-氧代吡咯烷-3-甲酸和(3S)5-氧代吡咯烷-3-甲酸;手性羧酸底物与硝酸铈胺的摩尔比为1:1~1:2,优选1:1.5;溶剂用乙腈和水(体积比1:1),反应温度为室温20-25℃,反应时间在0.5~1.5小时,优选1小时。Preferably, the carboxylic acid products are also diastereomers of each other, and are respectively reacted with the rare earth compound ceric amine nitrate (Ce(NH 4 ) 2 (NO 3 ) 6 ) to remove the protective group on N ( (3R) 5-oxopyrrolidine-3-carboxylic acid and (3S) 5-oxopyrrolidine-3-carboxylic acid are generated; molar ratio of chiral carboxylic acid substrate to ceric amine nitrate It is 1:1~1:2, preferably 1:1.5; the solvent is acetonitrile and water (volume ratio 1:1), the reaction temperature is room temperature 20-25°C, and the reaction time is 0.5~1.5 hours, preferably 1 hour.
作为优选,所述的S2中的产物(1R, 3R)或 (1R, 3S)-1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸甲酯也可以先与硝酸铈胺在乙腈和水中反应,脱除N上的保护基制得两个构型(3R或3S)的手性5-氧代吡咯烷-3-羧酸甲酯,这也是两个固体,可以通过重结晶纯化以提高其光学纯度;化学反应条件与(2)中描述的相同。然后再用氢氧化锂在甲醇和水做溶剂水解掉甲酯,分别得到两个目标产物(3R)5-氧代吡咯烷-3-甲酸和(3S)5-氧代吡咯烷-3-甲酸;各项化学反应条件与(1)中描述的相同;化学收率也近似。Preferably, the product (1R, 3R) or (1R, 3S)-1-(1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate in the S2 Methyl acid can also be reacted with ceric amine nitrate in acetonitrile and water to remove the protecting group on N to obtain two configurations (3R or 3S) of chiral 5-oxopyrrolidine-3-carboxylate methyl ester , which are also two solids that can be purified by recrystallization to improve their optical purity; the chemical reaction conditions are the same as described in (2). Then, the methyl ester was hydrolyzed with lithium hydroxide in methanol and water to obtain two target products (3R) 5-oxopyrrolidine-3-carboxylic acid and (3S) 5-oxopyrrolidine-3-carboxylic acid, respectively. ; The chemical reaction conditions are the same as those described in (1); the chemical yields are also similar.
本发明的另一目的在于提供一种手性5-氧代吡咯烷-3-甲酸的应用。Another object of the present invention is to provide an application of chiral 5-oxopyrrolidine-3-carboxylic acid.
本发明的有益效果是:The beneficial effects of the present invention are:
1、本发明方法首次以手性化合物R(+)-对甲氧基甲基苯甲胺(CAS: 22038-86-4)作为原料,与衣康酸二甲酯反应后引入了手性中心碳原子;而苯环对位甲氧基增加了中间体产物的的极性,有利于后处理和非对映异构体的纯化分离,具有一定的创新性。1. The method of the present invention uses the chiral compound R(+)-p-methoxymethylbenzylamine (CAS: 22038-86-4) as a raw material for the first time, and introduces a chiral center after reacting with dimethyl itaconic acid carbon atom; and the para-methoxy group of the benzene ring increases the polarity of the intermediate product, which is beneficial to the post-processing and the purification and separation of diastereomers, which is innovative to a certain extent.
2、第一步反应生成的一对手性非对映异构体可以方便地通过普通的硅胶柱层析得到分离,避免了使用其它手性拆分或者手性制备色谱等繁琐昂贵的方法与试剂,而且两个手性中间体的光学纯度(d.e值)都超过了90%。2. A chiral diastereomer generated in the first step reaction can be easily separated by ordinary silica gel column chromatography, avoiding the use of tedious and expensive methods and reagents such as other chiral separation or chiral preparative chromatography. , and the optical purity (d.e value) of both chiral intermediates exceeds 90%.
3、分离纯化后的第一步手性化合物继续用氢氧化锂(LiOH)水解甲酯得到的(1R,3R)或(1R, 3S)-1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸为固体,可以通过重结晶纯化提高其光学纯度(d.e值)。类似地,与硝酸铈胺反应脱除N上的保护基得到的两个构型手性(3R/3S)-5-氧代吡咯烷-3-羧酸甲酯也是固体,同样可以方便地通过重结晶纯化以增加其光学纯度(e.e.值)。这有效地保证了最终产物(3R)/(3S)-5-氧代吡咯烷-3-甲酸的光学纯度。3. (1R, 3R) or (1R, 3S)-1-(1-(4-methoxyphenyl) obtained by hydrolyzing methyl ester with lithium hydroxide (LiOH) for the first chiral compound after separation and purification )ethyl)-5-oxopyrrolidine-3-carboxylic acid is solid, and its optical purity (d.e value) can be improved by recrystallization and purification. Similarly, the two-configuration chiral (3R/3S)-5-oxopyrrolidine-3-carboxylate methyl ester obtained by reacting with ceric amine nitrate to remove the protecting group on N is also a solid, which can also be easily obtained by Purified by recrystallization to increase its optical purity (e.e. value). This effectively ensures the optical purity of the final product (3R)/(3S)-5-oxopyrrolidine-3-carboxylic acid.
4、本发明的合成工艺路线新颖、原料试剂廉价易得、后处理方便、反应条件温和、化学收率高;尤其巧妙地引入了手性中心,各手性中间体产物易于分离纯化,且具有较高的光学纯度;在手性药物合成中具有广泛的应用价值与潜力。4. The synthetic process route of the present invention is novel, the raw materials and reagents are cheap and easy to obtain, the post-processing is convenient, the reaction conditions are mild, and the chemical yield is high; especially, the chiral center is cleverly introduced, and each chiral intermediate product is easy to be separated and purified, and has High optical purity; wide application value and potential in chiral drug synthesis.
附图说明Description of drawings
为了更清楚地说明本发明实施例的技术方案,下面将对实施例描述所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to illustrate the technical solutions of the embodiments of the present invention more clearly, the following briefly introduces the accompanying drawings used in the description of the embodiments. Obviously, the drawings in the following description are only some embodiments of the present invention. For those of ordinary skill in the art, other drawings can also be obtained from these drawings without any creative effort.
图1是的化学结构示意图;Fig. 1 is the chemical structure schematic diagram of;
图2是衣康酸二甲酯(CAS:617-52-7)和R(+)-对甲氧基甲基苯甲胺(CAS: 22038-86-4)在180℃加热反应的化学反应式;Figure 2 is the chemical reaction of dimethyl itaconic acid (CAS: 617-52-7) and R(+)-p-methoxymethylbenzylamine (CAS: 22038-86-4) heated at 180 °C Mode;
图3是采用普通的硅胶柱层析分离法得到的化学反应式;Fig. 3 is the chemical reaction formula that adopts common silica gel column chromatography separation method to obtain;
图4是两个非对映异构体继续反应经过酯水解和脱去氮上保护基,或者先脱去氮上保护基再水解酯即可得到两个构型的目标手性化合物(R)-A和 (S)-A的化学反应式。Figure 4 shows that the two diastereomers continue to react through ester hydrolysis and removal of the protecting group on the nitrogen, or the target chiral compound (R) with two configurations can be obtained by first removing the protecting group on the nitrogen and then hydrolyzing the ester. Chemical formulas of -A and (S)-A.
具体实施方式Detailed ways
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其它实施例,都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings in the embodiments of the present invention. Obviously, the described embodiments are only a part of the embodiments of the present invention, but not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.
实施例1Example 1
在一圆底烧瓶中分别称量加入15.85克衣康酸二甲酯(0.1mol)和15.12克R(+)-对甲氧基甲基苯甲胺(0.1mol),硅油浴加热在180℃反应2-3小时,同时用分水器分出反应生成的甲醇;薄层板点样(TLC)两原料点消失,分出的甲醇大约3.5-4.0毫升,此时终止反应;反应油状残余物冷却后直接用200-300目普通硅胶进行柱层析分离,依次用石油醚(60-90℃)和乙酸乙酯做洗脱剂,体积比例(乙酸乙酯:石油醚)依次从1:3、1:2、1:1、2:1梯度洗脱,分别收集TLC上面荧光点产物和下面荧光点产物,减压旋转蒸发仪蒸干溶剂分别得到上面极性较小产物8.7克,收率62.8%;下面极性较大产物9.5克,收率68.6%。15.85 g of dimethyl itaconic acid (0.1 mol) and 15.12 g of R(+)-p-methoxymethylbenzylamine (0.1 mol) were weighed into a round-bottomed flask, and heated in a silicone oil bath at 180 °C. The reaction was carried out for 2-3 hours, and the methanol produced by the reaction was separated with a water separator; the two raw material points of thin layer plate spotting (TLC) disappeared, and the separated methanol was about 3.5-4.0 ml, and the reaction was terminated at this time; the reaction oily residue After cooling, directly use 200-300 mesh ordinary silica gel for column chromatography separation, and use petroleum ether (60-90 ° C) and ethyl acetate as eluents in turn, and the volume ratio (ethyl acetate: petroleum ether) is sequentially from 1:3 , 1:2, 1:1, 2:1 gradient elution, respectively collect the fluorescent point product above and the fluorescent point product below on TLC, evaporate the solvent under reduced pressure rotary evaporator to obtain 8.7 g of the product with less polar above, and the yield is 8.7 g. 62.8%; the lower polar product is 9.5 g, and the yield is 68.6%.
光学纯度d.e.值的测定,用C-18普通色谱柱以正己烷和甲醇作流动相,通过高压液相色谱(HPLC)测得非对映异构体的d.e.值分别为极性较小产物93.56%,极性较大产物95.23%。值得指出的是我们无法把色谱(TLC&HPLC)中极性较小或极性较大的产物与其绝对构型产物即(1R, 3R)或(1R, 3S)的1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸甲酯相对应。Determination of d.e. value of optical purity, using C-18 ordinary chromatographic column with n-hexane and methanol as mobile phase, the d.e. value of diastereomers measured by high pressure liquid chromatography (HPLC) is 93.56 for less polar products, respectively %, more polar products 95.23%. It is worth pointing out that we cannot compare the less polar or more polar products in chromatography (TLC & HPLC) with their absolute configuration products, i.e. 1-(1-(4-methyl) of (1R, 3R) or (1R, 3S). oxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate methyl ester corresponds.
核磁共振氢谱(1HNMR-CDCl3)结构鉴定:(1)、极性较小产物:δ(ppm):1.50(d, 3H),2.63-2.78(m, 2H), 3.09(q, 1H), 3.18(t, 1H), 3.52(dd, 1H), 3.72(s, 3H), 3.80(s, 3H), 5.44(q, 1H), 6.86(d, 2H), 7.22(d, 2H). (2)、极性较大产物:δ(ppm): 1.51(d, 3H), 2.63-2.78(m, 2H), 3.08-3.22(m, 2H), 3.52(m, 1H), 3.65(s, 3H), 3.80(s, 3H), 5.45(q, 1H), 6.86(d, 2H), 7.22(d, 2H). 从氢谱可以看出苯环对位甲氧基的甲基氢原子的化学位移明显不同,极性小的在3.72 ppm,极性大的在3.65ppm,这是1HNMR谱图区别两个手性非对映异构体的显著标志。Hydrogen nuclear magnetic resonance spectroscopy ( 1 HNMR-CDCl 3 ) structure identification: (1), less polar product: δ(ppm): 1.50(d, 3H), 2.63-2.78(m, 2H), 3.09(q, 1H) ), 3.18(t, 1H), 3.52(dd, 1H), 3.72(s, 3H), 3.80(s, 3H), 5.44(q, 1H), 6.86(d, 2H), 7.22(d, 2H) . (2) Product with higher polarity: δ(ppm): 1.51(d, 3H), 2.63-2.78(m, 2H), 3.08-3.22(m, 2H), 3.52(m, 1H), 3.65( s, 3H), 3.80(s, 3H), 5.45(q, 1H), 6.86(d, 2H), 7.22(d, 2H) The chemical shifts of atoms are obviously different, the less polar is 3.72 ppm, and the more polar is 3.65 ppm, which is a remarkable sign of distinguishing two chiral diastereomers in 1 HNMR spectrum.
实施例2Example 2
取上步反应极性较小的产物1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸甲酯4.8克(17.3mmol),用20mL甲醇溶解油状物后加入20mL水搅拌均匀,称量LiOH 0.65克(27.1mmol),氢氧化锂量少可慢慢直接加入固体,若量多可先溶于适量水后滴加;室温搅拌反应3-4小时,TLC点板检测底物点消失后终止反应;反应液用10%盐酸调pH=5~6,蒸去甲醇,加入适量水后用乙酸乙酯萃取三次,合并有机层用饱和食盐水和水各洗一次,无水硫酸钠或无水硫酸镁干燥,旋转蒸发干有机溶剂得到淡黄色固体;该固体用混合溶剂(正己烷:四氢呋喃=1:1)重结晶的白色结晶,静置过滤,母液浓缩后再次析出固体结晶,过滤合并烘干称重共4.1克,化学收率89.9%。Take 4.8 g (17.3 mmol) of methyl 1-(1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylate, the less polar product of the reaction in the previous step, with 20 mL After dissolving the oil in methanol, add 20 mL of water and stir evenly. Weigh 0.65 g (27.1 mmol) of LiOH. If the amount of lithium hydroxide is small, the solid can be added slowly. If the amount is large, it can be dissolved in an appropriate amount of water and added dropwise; After -4 hours, the TLC spot plate detected the disappearance of the substrate point to terminate the reaction; the reaction solution was adjusted to pH 5~6 with 10% hydrochloric acid, the methanol was evaporated, an appropriate amount of water was added, and then extracted three times with ethyl acetate, and the organic layers were combined with saturated common salt. Wash once with water and water, dry with anhydrous sodium sulfate or anhydrous magnesium sulfate, and rotate the organic solvent to dryness to obtain a light yellow solid; the solid is recrystallized with a mixed solvent (n-hexane:tetrahydrofuran=1:1) as a white crystal, Set for filtration, concentrate the mother liquor to separate out solid crystals again, filter, combine, dry, and weigh a total of 4.1 grams, with a chemical yield of 89.9%.
核磁共振氢谱(1HNMR-CDCl3),δ(ppm):1.50(d, 3H), 2.70-2.84(o&qq, 2H),3.09-3.16(m, 1H), 3.18-3.23(t, 1H), 3.56-3.60(q, 1H), 3.78(s, 3H), 5.45(q,1H), 5.78(br, 1H, COOH), 6.87(d, 2H), 7.22(d, 2H). 核磁共振碳谱13CNMR(CD Cl3),δ(ppm):16.10, 34.38, 35.86, 44.48, 48.94, 55.26, 114.01, 128.34, 131.27,159.05, 172.41, 176.21.Hydrogen nuclear magnetic resonance spectrum ( 1 HNMR-CDCl 3 ), δ(ppm): 1.50(d, 3H), 2.70-2.84(o&qq, 2H), 3.09-3.16(m, 1H), 3.18-3.23(t, 1H) , 3.56-3.60(q, 1H), 3.78(s, 3H), 5.45(q, 1H), 5.78(br, 1H, COOH), 6.87(d, 2H), 7.22(d, 2H). Carbon NMR Spectrum 13 CNMR (CD Cl 3 ), δ (ppm): 16.10, 34.38, 35.86, 44.48, 48.94, 55.26, 114.01, 128.34, 131.27, 159.05, 172.41, 176.21.
同样的反应方法与条件及后处理操作,投料极性较大的羧酸甲酯异构体4.5克经氢氧化锂水解得到另一构型的羧酸产物3.8克白色固体,化学收率88.9%。核磁共振氢谱(1HNMR-CDCl3),δ(ppm):1.51(d, 3H), 2.69-2.84(m, 2H), 3.08-3.13(m, 1H), 3.18-3.24(m, 1H), 3.52-3.60(m, 1H), 3.80(s, 3H), 5.44(q, 1H), 6.40(br, 1H, COOH),6.86(d, 2H), 7.22(d, 2H). 核磁共振碳谱13CNMR(CD Cl3), δ(ppm):16.43, 34.56,35.89, 44.68, 49.02, 55.38, 114.01, 128.34, 131.47, 159.13, 172.62, 176.32.The same reaction method, conditions and post-processing operation, 4.5 grams of methyl carboxylate isomers with higher polarity are hydrolyzed by lithium hydroxide to obtain 3.8 grams of white solid carboxylic acid products of another configuration, and the chemical yield is 88.9%. . Hydrogen nuclear magnetic resonance spectrum ( 1 HNMR-CDCl 3 ), δ(ppm): 1.51(d, 3H), 2.69-2.84(m, 2H), 3.08-3.13(m, 1H), 3.18-3.24(m, 1H) , 3.52-3.60(m, 1H), 3.80(s, 3H), 5.44(q, 1H), 6.40(br, 1H, COOH), 6.86(d, 2H), 7.22(d, 2H). Carbon NMR Spectrum 13 CNMR (CD Cl 3 ), δ (ppm): 16.43, 34.56, 35.89, 44.68, 49.02, 55.38, 114.01, 128.34, 131.47, 159.13, 172.62, 176.32.
实施例3Example 3
取例1中的两种手性异构体的任一种约2.5克(9mmol),加入40mL乙腈和40mL水溶解并搅拌均匀,称量硝酸铈胺8.1克(15mmol)分批加入,室温搅拌反应1小时左右,反应液颜色从棕红到红黄再到亮黄,TLC点板检测原料点消失,随后加入30mLNaHCO3水溶液终止反应,减压蒸出部分乙腈,加适量水后用乙酸乙酯萃取三次,合并有机层用水洗两次,无水硫酸钠或无水硫酸镁干燥,旋转蒸发干有机溶剂得到胶状物;该胶状物用快速硅胶柱层析分离,先用石油醚(60-90℃)和乙酸乙酯(5:1)做洗脱剂,收集上面强荧光点产物,蒸干后送1HNMR(CDCl3)鉴定为副产物对甲氧基乙酰苯;最后用乙酸乙酯:二氯甲烷(体积比1:1)洗脱出下面的产物点(碘显色),合并后蒸干溶剂得到白色固体约1.05克,收率81.4%,经核磁共振波谱结构鉴定为产物(3R/3S)-5-氧代吡咯烷-3-羧酸甲酯。Take about 2.5 g (9 mmol) of either of the two chiral isomers in Example 1, add 40 mL of acetonitrile and 40 mL of water to dissolve and stir evenly, weigh 8.1 g (15 mmol) of cerium nitrate and add it in batches, stir at room temperature The reaction was carried out for about 1 hour, the color of the reaction solution changed from brown-red to red-yellow to bright yellow, the TLC dot plate detected the disappearance of the raw material point, then 30 mL of NaHCO aqueous solution was added to terminate the reaction, part of acetonitrile was evaporated under reduced pressure, and an appropriate amount of water was added with ethyl acetate. Extracted three times, combined the organic layers and washed twice with water, dried with anhydrous sodium sulfate or anhydrous magnesium sulfate, and rotary evaporated the organic solvent to dryness to obtain a gum; the gum was separated by flash silica gel column chromatography, first with petroleum ether (60 -90℃) and ethyl acetate (5:1) as eluent, collect the product with strong fluorescent point above, evaporate to dryness and send it to 1 HNMR (CDCl 3 ) to identify the by-product p-methoxyacetophenone; finally, use ethyl acetate Ester: dichloromethane (volume ratio 1:1) eluted the following product point (iodine color development), after the combination, the solvent was evaporated to dryness to obtain about 1.05 g of white solid, the yield was 81.4%, and it was identified as the product by the nuclear magnetic resonance spectrum structure. (3R/3S)-5-oxopyrrolidine-3-carboxylate methyl ester.
核磁共振氢谱(1HNMR-CDCl3),δ(ppm):2.54-2.70(o, 2H), 3.12-3.40(q, 1H),3.59-3.67(m, 2H), 3.75(s, 3H), 6.96(br, 1H, NH). 核磁共振碳谱(13CNMR, CD Cl3),δ(ppm):33.15, 38.77, 44.40, 52.45, 173.16, 176.66.Hydrogen nuclear magnetic resonance spectrum ( 1 HNMR-CDCl 3 ), δ(ppm): 2.54-2.70(o, 2H), 3.12-3.40(q, 1H), 3.59-3.67(m, 2H), 3.75(s, 3H) , 6.96(br, 1H, NH). Carbon NMR ( 13 CNMR, CD Cl 3 ), δ(ppm): 33.15, 38.77, 44.40, 52.45, 173.16, 176.66.
实施例4Example 4
例2中的产物(1R, 3R)或(1R, 3S)-1-(1-(4-甲氧基苯基)乙基)-5-氧代吡咯烷-3-羧酸采用例3中的硝酸铈胺氧化脱去N上保护基,即得到手性目标产物(3R)/(3S)-5-氧代吡咯烷-3-甲酸(胶状物)。而例3中的产物(3R/3S)-5-氧代吡咯烷-3-羧酸甲酯则采取例2中的氢氧化锂水解掉甲酯,也同样得到手性目标产物(3R)/(3S)-5-氧代吡咯烷-3-甲酸(胶状物)。The product (1R, 3R) or (1R, 3S)-1-(1-(4-methoxyphenyl)ethyl)-5-oxopyrrolidine-3-carboxylic acid in Example 2 was used in Example 3 The ceric amine nitrate is oxidized to remove the protecting group on N, and the chiral target product (3R)/(3S)-5-oxopyrrolidine-3-carboxylic acid (gum) is obtained. And the product in Example 3 (3R/3S)-5-oxopyrrolidine-3-carboxylate methyl ester takes the lithium hydroxide in Example 2 to hydrolyze the methyl ester, and also obtains the chiral target product (3R)/ (3S)-5-Oxopyrrolidine-3-carboxylic acid (gum).
在本说明书的描述中,参考术语“一个实施例”、“示例”、“具体示例”等的描述意指结合该实施例或示例描述的具体特征、结构、材料或者特点包含于本发明的至少一个实施例或示例中。在本说明书中,对上述术语的示意性表述不一定指的是相同的实施例或示例。而且,描述的具体特征、结构、材料或者特点可以在任何的一个或多个实施例或示例中以合适的方式结合。In the description of this specification, description with reference to the terms "one embodiment," "example," "specific example," etc. means that a particular feature, structure, material, or characteristic described in connection with the embodiment or example is included in at least one aspect of the present invention. in one embodiment or example. In this specification, schematic representations of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the particular features, structures, materials or characteristics described may be combined in any suitable manner in any one or more embodiments or examples.
以上公开的本发明优选实施例只是用于帮助阐述本发明。优选实施例并没有详尽叙述所有的细节,也不限制该发明仅为所述的具体实施方式。显然,根据本说明书的内容,可作很多的修改和变化。本说明书选取并具体描述这些实施例,是为了更好地解释本发明的原理和实际应用,从而使所属技术领域技术人员能很好地理解和利用本发明。本发明仅受权利要求书及其全部范围和等效物的限制。The above-disclosed preferred embodiments of the present invention are provided only to help illustrate the present invention. The preferred embodiments do not exhaust all the details, nor do they limit the invention to only the described embodiments. Obviously, many modifications and variations are possible in light of the content of this specification. These embodiments are selected and described in this specification in order to better explain the principles and practical applications of the present invention, so that those skilled in the art can well understand and utilize the present invention. The present invention is to be limited only by the claims and their full scope and equivalents.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211025942.6A CN115197115B (en) | 2022-08-25 | 2022-08-25 | Preparation method and application of chiral 5-oxo pyrrolidine-3-carboxylic acid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211025942.6A CN115197115B (en) | 2022-08-25 | 2022-08-25 | Preparation method and application of chiral 5-oxo pyrrolidine-3-carboxylic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115197115A true CN115197115A (en) | 2022-10-18 |
CN115197115B CN115197115B (en) | 2024-11-08 |
Family
ID=83571766
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211025942.6A Active CN115197115B (en) | 2022-08-25 | 2022-08-25 | Preparation method and application of chiral 5-oxo pyrrolidine-3-carboxylic acid |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115197115B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013107855A (en) * | 2011-11-22 | 2013-06-06 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition |
CN104520300A (en) * | 2012-06-04 | 2015-04-15 | 第一三共株式会社 | Imidazo[1,2-b]pyridazine derivative as kinase inhibitor |
CN105555780A (en) * | 2013-07-31 | 2016-05-04 | 吉利德科学公司 | Syk inhibitors |
US20170107240A1 (en) * | 2013-07-03 | 2017-04-20 | Takeda Pharmaceutical Company Limited | Amide compound |
BR102016020905A2 (en) * | 2016-09-09 | 2018-03-20 | Boehringer Ingelheim International Gmbh | REPLACED HETEROARIS PIRAZOLIL AND ITS USE AS MEDICINAL PRODUCTS |
CN108026080A (en) * | 2015-09-11 | 2018-05-11 | 勃林格殷格翰国际有限公司 | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments |
-
2022
- 2022-08-25 CN CN202211025942.6A patent/CN115197115B/en active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013107855A (en) * | 2011-11-22 | 2013-06-06 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition |
CN104520300A (en) * | 2012-06-04 | 2015-04-15 | 第一三共株式会社 | Imidazo[1,2-b]pyridazine derivative as kinase inhibitor |
US20170107240A1 (en) * | 2013-07-03 | 2017-04-20 | Takeda Pharmaceutical Company Limited | Amide compound |
CN105555780A (en) * | 2013-07-31 | 2016-05-04 | 吉利德科学公司 | Syk inhibitors |
CN108026080A (en) * | 2015-09-11 | 2018-05-11 | 勃林格殷格翰国际有限公司 | Pyrazolyl-substituted heteroaryl compounds and their use as medicaments |
BR102016020905A2 (en) * | 2016-09-09 | 2018-03-20 | Boehringer Ingelheim International Gmbh | REPLACED HETEROARIS PIRAZOLIL AND ITS USE AS MEDICINAL PRODUCTS |
Non-Patent Citations (3)
Title |
---|
FULVIA FELLUGA等: "A chemoenzymatic approach to the synthesis of enantiomerically pure aza analogues of paraconic acid methyl ester and both enantiomers of methyl β-proline", 《TETRAHEDRON: ASYMMETRY》, vol. 12, no. 23, pages 3241 * |
ROBERTA GALEAZZI等: "Conformationally restricted analogues of both (S)-b-homoserine and (S)-aspartic acid from chiral 3-acylamino pyrrolidin-2-ones", 《TETRAHEDRON》, vol. 61, no. 23, pages 5465 * |
刘耕陶,等: "《中草药现代研究 第5卷》", 中国协和医科大学出版社, pages: 310 * |
Also Published As
Publication number | Publication date |
---|---|
CN115197115B (en) | 2024-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN114846008B (en) | Pyrimidine compound with fructokinase (KHK) inhibiting effect | |
JP2691442B2 (en) | Novel proline derivative | |
CN116751136A (en) | Novel preparation method of oxo-pyridine compound and key intermediate | |
CN116621728A (en) | Novel preparation method and key intermediates of oxopyridine compounds | |
HUT68255A (en) | Process for the preparation of beta-phenylisoserine derivatives and use thereof | |
EP2914574B1 (en) | New process | |
CA2980071A1 (en) | Method for preparation of (4s)-4-[4-cyano-2-(methylsulfonyl)phenyl]-3,6-dimethyl-2-oxo-1-[3-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydro pyrimidine-5-carbonitrile | |
RU2709493C1 (en) | Method of producing roxadustat | |
CN115197115B (en) | Preparation method and application of chiral 5-oxo pyrrolidine-3-carboxylic acid | |
US5554764A (en) | Preparation of pyrrol and oxazole compounds: formation of C-acyl-α-amino acid esters therefrom | |
Faigl et al. | Highly efficient stereoconservative syntheses of new, bifunctional atropisomeric organocatalysts | |
CN108299269B (en) | A kind of synthetic method of MC-1568 | |
CN111777554A (en) | Method for synthesizing cisatracurium besilate | |
CN111662233B (en) | Method for synthesizing 4-chloro-1H-imidazole-2-carboxylic acid ethyl ester by one-step method | |
CN115819412B (en) | A synthetic method of N-heterocyclic BET bromodomain inhibitor and its intermediates | |
JPH03118837A (en) | Chiral induction catalyst | |
JP3432880B2 (en) | Preparation of optically active azaspiro compounds | |
CN110105361B (en) | A kind of preparation method of Evodiakine and derivative thereof | |
CN108997232B (en) | Method for synthesizing histone deacetylase inhibitor | |
CN116606238A (en) | A kind of N-Boc-3-nitroindole and preparation method thereof | |
FI68830C (en) | DL-ELLER D-TRANS-8-FLUORO-5- (P-FLUORPHENYL) -2,3,4,4A, 5,9B-HEXSAHYDRO-1H-PYRIDO (4,3-B) INDOL SOM ANVAENDS SOM MELLANPROTUKT VID FRAMSTAELLNING AV THERAPEUTIC ANVAENDBARA 2-SUBSTITUERADE DL- OCH D-TRANS-8-FLUOR-5- (P-FLUORPHENYL) -2,3,4,4A, 5,9B-HEXSAHYDRO-1H-PYRIDO (4,3-B) INDOLER | |
KR100483317B1 (en) | METHOD FOR THE PREPARATION OF α-PHENYL-α-PROPOXYBENZENEACETIC ACID 1-METHYL-4-PIPERIDINYL ESTER HYDROCHLORIDE | |
CN118993929A (en) | Sitagliptin Process for the preparation of intermediates | |
CN115074404A (en) | A kind of synthetic method of (2R, 4R)-2-amino-4-methylnonanoic acid | |
KR20100054628A (en) | Method for preparing binaphthol aldehyde derivatives and intermediate thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |